Lọc theo danh mục
  • Năm xuất bản
    Xem thêm
  • Lĩnh vực
liên kết website
Lượt truy cập
 Lượt truy cập :  30,242,094
  • Công bố khoa học và công nghệ Việt Nam

76.29.49

Y học lâm sàng

Lê Văn Quảng, Lê Đình Roanh, Trần Minh Tùng(1)

Nghiên cứu kết quả điều trị ung thư lưỡi di động giai đoạn III - IV (MO) bằng hóa chất phác đồ Cisplatin và 5Fluorouracil bổ trợ trước phẫu thuật và/hoặc xạ trị

To study the result of treatment in neoadjuvant chemotherapy with cisplatin-5 fluorouracil in patients with stage III-IV (MO) mobile tongue cancer followed by surgery and/or radiation

Y học Việt Nam

2014

1

88-93

1859-1868

Objective: The result of' survival rates in neoadjuvant chemotherapy with cisplatin and 5 f1uorouracil in patients with stage III-IV(MO) mobile tongue cancer followed by surgery and/or radiation. Patients and Methods: 117 caSes with stage IIIIV(MO) mobile tongue cancer, were investigated in this prospective study, treated by neoadjuvant chemotherapy with CF regimen followed by surgery and/or radiation at K hospital and Ha Noi medical university hospital from 2002 to 201.0. Result: Overall 01year, 02 year, 03 year, 04 year 'survival rate were 75,2 percent; 57,5 percent; 45,2 percent; 39,2 percent. The five-year survival rate was 22.4 percent. The five-year survival rate for stage N0 was 27,2 percent and N1-N3 was 13,3 percent ( p 0,05). The five-year survival rate for stage III was 42.5 percent and stage IV was 11.3 percent ( p 0.05). The five-year survival rate for chemotherapy plus surgery group and chemotherapy plus radiotherapy were 33.1 percent vs 11 percent. The five-year survival rate for chemotherapy plus surgery group and chemotherapy, surgery plus radiotherapy group and chemotherapy plus radiotherapy were 32.4 percent; 32.2 percent vs 7.3 percent percent. Conclusions: Result treatment with stage III-IV(MO) mobile tongue cancer with neoadjuvant chemotherapy improved the rate of tumour response, many patients could be treated by surgery after neoadjuvant chemotherapy. Neoadjuvant cisplatin and 5 fluorouracil regimen improves survival in tongue cancer patients.

TTKHCNQG, CVv 46